Janus Henderson Group PLC Arcellx, Inc. Transaction History
Janus Henderson Group PLC
- $207 Billion
- Q3 2025
A detailed history of Janus Henderson Group PLC transactions in Arcellx, Inc. stock. As of the latest transaction made, Janus Henderson Group PLC holds 1,013,921 shares of ACLX stock, worth $91.2 Million. This represents 0.04% of its overall portfolio holdings.
Number of Shares
1,013,921
Previous 1,023,582
0.94%
Holding current value
$91.2 Million
Previous $67.4 Million
23.5%
% of portfolio
0.04%
Previous 0.03%
Shares
14 transactions
Others Institutions Holding ACLX
# of Institutions
226Shares Held
51.4MCall Options Held
85.4KPut Options Held
113K-
T. Rowe Price Investment Management, Inc. Baltimore, MD6.35MShares$572 Million0.32% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY4.65MShares$418 Million12.3% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.91MShares$352 Million0.0% of portfolio
-
Black Rock Inc. New York, NY3.52MShares$316 Million0.0% of portfolio
-
Nea Management Company, LLC Timonium, MD3.05MShares$274 Million15.63% of portfolio
About Arcellx, Inc.
- Ticker ACLX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,819,200
- Market Cap $3.94B
- Description
- Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...